Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
19 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND ABT-199 [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)
Condition: Mantle Cell Lymphoma
Interventions: Drug: ABT-199;   Drug: Ibrutinib
2 Recruiting A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib + GA101 +GDC-0199
3 Not yet recruiting A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions: Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: ABT-199;   Drug: Ibrutinib;   Drug: Rituximab
4 Recruiting A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: CHOP;   Drug: GDC-0199;   Drug: obinutuzumab;   Drug: rituximab [MabThera/Rituxan]
5 Not yet recruiting Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)
Conditions: Primary Lymphoid Haematopoietic Neoplasms;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Venetoclax;   Drug: Ibrutinib;   Drug: Allopurinol
6 Recruiting A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Had No Response to Previous Cancer Treatments Including Subjects Missing Part of Their Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Venetoclax
7 Not yet recruiting Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Conditions: Follicular Lymphoma;   Non-Hodgkin's Lymphoma Follicular;   Non-Hodgkin's Lymphoma, Adult High Grade
Interventions: Drug: Induction Venetoclax;   Drug: Maintenance Venetoclax
8 Not yet recruiting A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Venetoclax
9 Recruiting A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor.
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Venetoclax
10 Recruiting Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Conditions: Refractory Follicular Lymphoma;   Relapsed Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax
11 Recruiting Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
Condition: Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: Venetoclax;   Drug: Obinutuzumab
12 Recruiting Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax
13 Available Expanded Access to Venetoclax
Conditions: Chronic Lymphocytic Leukemia (CLL);   Multiple Myeloma;   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma
Intervention: Drug: Venetoclax
14 Recruiting Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Bcl-2 Inhibitor GDC-0199;   Biological: Obinutuzumab;   Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
15 Recruiting A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine;   Drug: Obinutuzumab;   Drug: Rituximab;   Drug: Venetoclax
16 Recruiting Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Venetoclax
17 Recruiting Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: Idelalisib;   Drug: Venetoclax
18 Not yet recruiting Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Conditions: Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Venetoclax
19 Recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Venetoclax

Study has passed its completion date and status has not been verified in more than two years.